Lin Huamao M, Pan Xiaoyun, Biller Alyssa, J Covey Kyla, Huang Hui, Sugarman Rebecca, Scipione Fatima, West Howard
Millennium Pharmaceuticals, Inc., Cambridge, MA 02139, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Invitae Corporation, San Francisco, CA 94103, USA.
Lung Cancer Manag. 2020 Nov 20;10(1):LMT42. doi: 10.2217/lmt-2020-0018.
Evaluate real-world patient preferences, experiences and outcomes (health-related quality of life [HRQoL]) from patients with anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer (NSCLC) utilizing the ALKConnect Patient Insight Network.
PATIENTS & METHODS: Demographics, disease history/status/treatment, patient preferences and HRQoL (MD Anderson Symptom Inventory lung cancer module, reported as symptom severity and interference) were evaluated for US adults with ALK+ NSCLC.
Among 104 patients (median age: 53.0 years, 67.3% female, 40.0% employed), HRQoL and 3-month delay in disease progression were important treatment attributes. Burdensome symptoms included fatigue and disturbed sleep. Symptoms interfered most with work and day-to-day activity. Higher HRQoL was associated with ALK tyrosine kinase inhibitor (TKI) treatment and employment.
ALKConnect demonstrated that disease progression, HRQoL, fatigue/sleep, ALK TKIs and employment matter in ALK+ NSCLC.
利用ALKConnect患者洞察网络评估间变性淋巴瘤激酶阳性（ALK+）非小细胞肺癌（NSCLC）患者的真实世界患者偏好、体验和结局（健康相关生活质量[HRQoL]）。
对美国成年ALK+ NSCLC患者的人口统计学、疾病史/状态/治疗、患者偏好和HRQoL（MD安德森症状量表肺癌模块，以症状严重程度和干扰程度报告）进行评估。
在104例患者中（中位年龄：53.0岁，67.3%为女性，40.0%就业），HRQoL和疾病进展延迟3个月是重要的治疗属性。令人负担沉重的症状包括疲劳和睡眠障碍。症状对工作和日常活动干扰最大。较高的HRQoL与ALK酪氨酸激酶抑制剂（TKI）治疗和就业相关。
ALKConnect表明，疾病进展、HRQoL、疲劳/睡眠、ALK TKIs和就业在ALK+ NSCLC中很重要。
